• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Albireo Pharma Inc.

    2/24/23 5:24:53 PM ET
    $ALBO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALBO alert in real time by email
    SC 13G 1 d395508dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

     

    Albireo Pharma, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

    01345P106

    (CUSIP Number)

    February 17, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed :

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 01345P106    SCHEDULE 13G    Page 2  of 14 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Double Black Diamond Offshore Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      178,146

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      178,146

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      178,146

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      1.0%

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    2


    CUSIP No. 01345P106    SCHEDULE 13G    Page 3  of 14 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Black Diamond Arbitrage Offshore Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      632,155

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      632,155

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      632,155

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.0%

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    3


    CUSIP No. 01345P106    SCHEDULE 13G    Page 4  of 14 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      EDCA 2019 Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      208,795

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      208,795

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      208,795

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      1.0%

    12  

      TYPE OF REPORTING PERSON

     

      PN

     

    4


    CUSIP No. 01345P106    SCHEDULE 13G    Page 5  of 14 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Corbin Hedged Equity Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      55,904

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      55,904

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      55,904

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.3%

    12  

      TYPE OF REPORTING PERSON

     

      PN

     

    5


    CUSIP No. 01345P106    SCHEDULE 13G    Page 6  of 14 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Carlson Capital, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      1,075,000

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      1,075,000

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,075,000

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.2%

    12  

      TYPE OF REPORTING PERSON

     

      PN, IA

     

     

    6


    CUSIP No. 01345P106    SCHEDULE 13G    Page 7  of 14 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Asgard Investment Corp. II

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      1,075,000

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      1,075,000

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,075,000

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.2%

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

     

     

    7


    CUSIP No. 01345P106    SCHEDULE 13G    Page 8  of 14 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Clint D. Carlson

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      1,075,000

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      1,075,000

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,075,000

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.2%

    12  

      TYPE OF REPORTING PERSON

     

      IN

     

    8


    Item 1(a).

    NAME OF ISSUER

    Albireo Pharma, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    53 State Street, 19th Floor

    Boston, MA 02109

     

    Item 2(a).

    NAME OF PERSON FILING

    This statement is filed by:

    (i) Double Black Diamond Offshore Ltd., a Cayman Islands exempted company (the “Double Offshore”), with respect to Common Stock, par value $0.01 per share, of the Issuer (the “Common Stock”) held or beneficially owned directly by it;

    (ii) Black Diamond Arbitrage Offshore Ltd., a Cayman Islands exempted company (“Arbitrage Offshore”), with respect to the Common Stock held or beneficially owned directly by it;

    (iii) EDCA 2019 Fund, L.P., a Delaware limited partnership (“EDCA”), with respect to the Common Stock held or beneficially owned directly by it;

    (iv) Corbin Hedged Equity Fund, L.P., a Delaware Limited Partnership (“Corbin,” and together with Double Offshore, Arbitrage Offshore and EDCA, the “Funds”), with respect to the Common Stock directly held by it;

    (v) Carlson Capital, L.P., a Delaware limited partnership (“Carlson Capital”), which serves as the investment manager to the Funds with respect to any shares of Common Stock held by the Funds;

    (vi) Asgard Investment Corp. II, a Delaware corporation (“Asgard II”), which serves as the general partner of Carlson Capital, with respect to the Common Stock directly held by the Funds; and

    (vii) Mr. Clint D. Carlson, a United States citizen (“Mr. Carlson”), who is the sole stockholder of Asgard II and serves as president of Asgard II and Carlson Capital, with respect to the Common Stock directly held by the Funds.

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons”.

    The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

     

    Item 2(b).

    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE

    The address of the principal business office of each of the Reporting Persons is 2100 McKinney Avenue, Suite 1900, Dallas, Texas 75201.

     

    9


    Item 2(c).

    CITIZENSHIP

    Carlson Capital, EDCA and Corbin are Delaware limited partnerships. Double Offshore and Arbitrage Offshore are Cayman Islands exempted company. Asgard II is a Delaware corporation. Mr. Carlson is a United States citizen.

     

    Item 2(d).

    TITLE OF CLASS OF SECURITIES

    Common Stock, par value $0.01 per share (the “Common Stock”).

     

    Item 2(e).

    CUSIP No.

    01345P106

     

    Item 3.

    IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13D-1(B), OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)    ☒    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
    (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________

     

    10


    Item 4.

    OWNERSHIP

     

      A.

    Double Offshore:

     

      (a)

    Amount beneficially owned: 178,146 shares of Common Stock

     

      (b)

    Percent of class: 1.0%

     

      (c)

    (i)      Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 178,146

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 178,146

     

      B.

    Arbitrage Offshore:

     

      (a)

    Amount beneficially owned: 632,155 shares of Common Stock

     

      (b)

    Percent of class: 3.0%

     

      (c)

    (i)      Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 632,155

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 632,155

     

      C.

    EDCA:

     

      (a)

    Amount beneficially owned: 208,795 shares of Common Stock

     

      (b)

    Percent of class: 1.0%

     

      (c)

    (i)      Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 208,795

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 208,795

     

      D.

    Corbin:

     

      (a)

    Amount beneficially owned: 55,904 shares of Common Stock

     

      (b)

    Percent of class: 0.3%

     

      (c)

    (i)      Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 55,904

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 55,904

     

      E.

    Carlson Capital:

     

      (a)

    Amount beneficially owned: 1,075,000

     

      (b)

    Percent of class: 5.2%

     

      (c)

    (i)      Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 1,075,000

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 1,075,000

     

      F.

    Asgard II:

     

      (a)

    Amount beneficially owned: 1,075,000

     

      (b)

    Percent of class: 5.2%

     

      (c)

    (i)      Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 1,075,000

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 1,075,000

     

      G.

    Mr. Carlson:

     

      (a)

    Amount beneficially owned: 1,075,000

     

      (b)

    Percent of class: 5.2%

     

      (c)

    (i)      Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 1,075,000

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 1,075,000

     

    11


    The percentages reported in this Schedule 13G are based on 20,863,673 shares of Common Stock outstanding as of January 20, 2023, as reported in the Issuer’s Tender Offer Statement filed with the Securities and Exchange Commission on January 23, 2023. In addition, as of February 23, 2023, the Reporting Persons’ beneficial ownership increased to 1,375,000.00 (6.6%) from 1,075,000 (5.2%) shares of Common Stock.

     

    Item 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

    Not applicable.

     

    Item 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

    Not applicable.

     

    Item 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

    Not applicable.

     

    Item 9.

    NOTICE OF DISSOLUTION OF GROUP

    Not applicable.

     

    Item 10.

    CERTIFICATION

    Each of the Reporting Persons hereby makes the following certification:

    By signing below, each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    12


    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: February 24, 2023

     

    DOUBLE BLACK DIAMOND OFFSHORE LTD.
    By: Carlson Capital, L.P., its investment manager
    By: Asgard Investment Corp. II, its general partner
    By:  

    /s/ Clint D. Carlson

    Name:   Clint D. Carlson
    Title:   President
    BLACK DIAMOND ARBITRAGE OFFSHORE LTD.
    By: Carlson Capital, L.P., its investment manager
    By: Asgard Investment Corp. II, its general partner
    By:  

    /s/ Clint D. Carlson

    Name:   Clint D. Carlson
    Title:   President
    EDCA 2019 Fund, L.P.
    By: Carlson Capital, L.P., its investment manager
    By: Asgard Investment Corp. II, its general partner
    By:  

    /s/ Clint D. Carlson

    Name:   Clint D. Carlson
    Title:   President
    CORBIN HEDGED EQUITY FUND, L.P.
    By: Carlson Capital, L.P., its investment manager
    By: Asgard Investment Corp. II, its general partner
    By:  

    /s/ Clint D. Carlson

    Name:   Clint D. Carlson
    Title:   President
    CARLSON CAPITAL, L.P.
    By: Asgard Investment Corp. II, its general partner
    By:  

    /s/ Clint D. Carlson

    Name:   Clint D. Carlson
    Title:   President

     

    13


    ASGARD INVESTMENT CORP. II
    By:  

    /s/ Clint D. Carlson

    Name:   Clint D. Carlson
    Title:   President
    CLINT D. CARLSON

    /s/ Clint D. Carlson

     

    14

    Get the next $ALBO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALBO

    DatePrice TargetRatingAnalyst
    1/9/2023$53.00 → $42.00Outperform → Neutral
    Wedbush
    9/8/2022$55.00Buy
    Guggenheim
    3/28/2022$75.00Outperform
    Wedbush
    11/5/2021$79.00 → $80.00Buy
    HC Wainwright & Co.
    9/16/2021$82.00 → $84.00Outperform
    Wedbush
    7/21/2021$73.00 → $82.00Outperform
    Wedbush
    More analyst ratings

    $ALBO
    Leadership Updates

    Live Leadership Updates

    See more
    • Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors

      – Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief Medical Officer at Arena Pharmaceuticals, brings significant global drug development and commercialization expertise – Two appointments strengthen Company's ability to scale up global drug development and grow the portfolio BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the appointments of two scientific leaders, Drs. Paul Streck and Craig Hopki

      12/6/22 8:30:00 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Albireo Appoints New Members to Board of Directors

      – Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston Children's Hospital, bring significant global drug development, financial and commercial operations expertise to Albireo BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the appointments of Habib Dable and Susan Alesina to its Board of Directors — two experienced, strategic leaders with vast pharmaceutical and biotech expertise in business development, operations and commercialization. T

      8/10/22 8:30:00 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Noema Pharma Appoints Michael Gutch as Chief Financial Officer

      BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer. Dr. Gutch has extensive experience in the healthcare and pharmaceutical industries and venture capital investment. He served as Executive Director of Corporate Development and Head of Equities at AstraZeneca and was most recently Chief Business Officer and Chief Financial Officer at Entasis Therapeutics, an AstraZeneca spin-off, where he was involved in the company's private financing rounds, its NASDAQ listing in 2018 and in the strategic partneri

      2/28/22 8:00:00 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALBO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BYLVAY issued to ALBIREO PHARMA INC

      Submission status for ALBIREO PHARMA INC's drug BYLVAY (ORIG-1) with active ingredient ODEVIXIBAT has changed to 'Approval' on 07/20/2021. Application Category: NDA, Application Number: 215498, Application Classification: Type 1 - New Molecular Entity

      7/21/21 11:28:05 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALBO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

      Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 Extension allows for the satisfaction of the HSR Act related condition as outlined in the Merger AgreementAlbireo stockholders are encouraged to tender their shares to the offer today PARIS, FRANCE, 22 February 2023 – Ipsen S.A. ((Euronext: IPN, OTC:IPSEY) today announced that Anemone Acquisition Corp. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the "Shares") of Albireo Pharma, Inc. (NASDAQ:ALBO) (Albireo) at a price of $42.00 per share, net to the holder

      2/22/23 1:00:00 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

      Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's supplemental New Drug Application (sNDA) and issued a Prescription Drug User Fee Act (PDUFA) action date of June 15, 2023 for a second Bylvay (odevixi

      2/14/23 8:30:00 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

      Transaction focused on Bylvay® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen's long-term strategy for expanding the scope of its Rare Disease portfolio and pipeline Ipsen to commence cash tender offer to acquire all issued and outstanding shares of Albireo for $42.00 per share plus a contingent value right (CVR) of $10.00 per share related to the U.S. FDA approval of Bylvay in biliary atresia Regulatory News: Ipsen (OTC:IPSEY) and Albireo (NASDAQ:ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acqu

      1/9/23 1:00:00 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALBO
    SEC Filings

    See more

    $ALBO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 15-12G filed by Albireo Pharma Inc.

      15-12G - ALBIREO PHARMA, INC. (0001322505) (Filer)

      3/14/23 3:36:01 PM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Albireo Pharma Inc.

      EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)

      3/9/23 12:15:12 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Albireo Pharma Inc.

      EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)

      3/9/23 12:15:14 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Albireo Pharma Inc. (Amendment)

      SC 13G/A - ALBIREO PHARMA, INC. (0001322505) (Subject)

      2/14/24 8:33:48 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Albireo Pharma Inc. (Amendment)

      SC 13G/A - ALBIREO PHARMA, INC. (0001322505) (Subject)

      4/10/23 11:22:45 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Albireo Pharma Inc.

      SC 13G - ALBIREO PHARMA, INC. (0001322505) (Subject)

      3/2/23 4:26:20 PM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALBO
    Financials

    Live finance-specific insights

    See more
    • Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

      Transaction focused on Bylvay® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen's long-term strategy for expanding the scope of its Rare Disease portfolio and pipeline Ipsen to commence cash tender offer to acquire all issued and outstanding shares of Albireo for $42.00 per share plus a contingent value right (CVR) of $10.00 per share related to the U.S. FDA approval of Bylvay in biliary atresia Regulatory News: Ipsen (OTC:IPSEY) and Albireo (NASDAQ:ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acqu

      1/9/23 1:00:00 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Albireo Reports Q3 2022 Financial Results and Business Update

      Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD Positive Bylvay Phase 3 ASSERT topline data in ALGS presented at AASLD; submissions on track Completed enrollment in BOLD study in biliary atresia, third Bylvay Phase 3 programCompany to host a conference call and webcast today at 4:30 p.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat rare pediatric and adult liver diseases, today provided a business update and reported financial results

      11/8/22 4:01:00 PM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Albireo to Report Q3 2022 Financial Results on November 8, 2022

      BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 8, 2022, to provide a business update and review the company's financial results for the quarter ended September 30, 2022. To access the live conference call by phone, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international), and provide the access code 10020423. A live audio webcast will be accessible from the Investors page at ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that partici

      10/31/22 8:30:00 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALBO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Albireo Pharma downgraded by Wedbush with a new price target

      Wedbush downgraded Albireo Pharma from Outperform to Neutral and set a new price target of $42.00 from $53.00 previously

      1/9/23 8:38:39 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Albireo Pharma with a new price target

      Guggenheim initiated coverage of Albireo Pharma with a rating of Buy and set a new price target of $55.00

      9/8/22 7:16:48 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Albireo Pharma with a new price target

      Wedbush initiated coverage of Albireo Pharma with a rating of Outperform and set a new price target of $75.00

      3/28/22 8:34:41 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALBO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Chiswell David closing all direct ownership in the company

      4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)

      3/3/23 6:05:13 AM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Alesina Susan

      4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)

      3/2/23 5:02:24 PM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Okey Stephanie

      4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)

      3/2/23 5:01:28 PM ET
      $ALBO
      Biotechnology: Pharmaceutical Preparations
      Health Care